Provigil Manufacturing, Supply & Shortage History

From Cephalon to Teva: The Brand-Name Era (1998 to 2011)

Modafinil received FDA approval on December 24, 1998 (NDA 020717) for the treatment of excessive daytime sleepiness associated with narcolepsy, making it the first non-amphetamine wakefulness-promoting agent available in the United States [1]. Cephalon Inc., based in West Chester, Pennsylvania, held the original new drug application and marketed the product as Provigil.

The approval rested on key data from the US Modafinil in Narcolepsy Multicenter Study Group, published in Annals of Neurology in 1998. That trial enrolled 283 patients with narcolepsy across nine centers and demonstrated that modafinil 200 mg and 400 mg significantly reduced Epworth Sleepiness Scale (ESS) scores compared with placebo, without the cardiovascular or abuse-liability profile typical of amphetamine-class stimulants [2]. The FDA later expanded approved indications to include shift work disorder and as an adjunct in obstructive sleep apnea (2004), based on additional controlled trials submitted under supplemental NDAs [3].

Cephalon's manufacturing relied on API synthesized through the diphenylmethyl sulfinyl acetamide pathway. The company sourced its API from facilities in France and India. During the brand-only era (1998 to 2012), supply remained stable. No FDA Drug Shortage entries appeared for Provigil during this period, according to FDA Drug Shortage Database records [4].

In October 2011, Teva Pharmaceutical Industries completed its acquisition of Cephalon for approximately $6.8 billion [5]. This acquisition gave Teva control of the Provigil NDA, manufacturing infrastructure, and the armodafinil (Nuvigil) franchise. The deal also positioned Teva as both brand-name holder and eventual generic supplier, a dual role that would shape the competitive dynamics of modafinil's generic market.

Generic Entry and Patent Settlement Controversies (2006 to 2012)

Four generic manufacturers filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications between 2003 and 2006, challenging Cephalon's patents on modafinil. These filers included Mylan, Teva, Ranbaxy, and Barr Pharmaceuticals.

Cephalon responded with patent infringement lawsuits. Between 2005 and 2006, Cephalon settled with all four challengers through agreements that included payment provisions and delayed generic entry dates. The Federal Trade Commission (FTC) investigated these settlements as potential "pay-for-delay" arrangements, filing a complaint in 2008 alleging that Cephalon paid a combined $200 million to keep generics off the market until April 2012 [6]. The FTC settlement (finalized in 2015) required Teva/Cephalon to pay $1.2 billion to resolve claims that the agreements violated antitrust law [7].

Generic modafinil 100 mg and 200 mg tablets launched in April 2012. Teva itself was among the first generic suppliers, alongside Mylan (now Viatris), Par Pharmaceutical (Endo International), and others. Within 12 months of generic entry, brand Provigil lost over 80% of its prescription volume. The average wholesale price for generic modafinil dropped from roughly $8 to $12 per tablet to under $1 per tablet by 2014 [8].

How Modafinil Works: Mechanism Relevant to Manufacturing

Understanding modafinil's pharmacology is relevant to its manufacturing profile because the molecule's chirality and relatively complex sulfinyl group affect both synthesis difficulty and API stability. Modafinil is a racemic compound consisting of equal parts R-modafinil (armodafinil) and S-modafinil.

The exact mechanism of action remains incompletely characterized, but convergent evidence points to selective dopamine reuptake inhibition as the primary driver. A 2009 PET imaging study by Volkow et al. (JAMA) demonstrated that modafinil 200 mg and 400 mg blocked dopamine transporters (DAT) in the human brain, increasing dopamine levels in the nucleus accumbens [9]. This finding clarified decades of debate about whether modafinil acted through dopaminergic pathways.

Beyond DAT inhibition, modafinil increases extracellular norepinephrine and histamine in the hypothalamus and cortex [10]. It also activates orexin/hypocretin neurons in the lateral hypothalamus, though it is not an orexin receptor agonist itself. These multiple downstream effects on wake-promoting circuits explain its clinical efficacy in narcolepsy and other hypersomnia conditions without the sympathomimetic burden of traditional stimulants.

The sulfinyl functional group (S=O) in modafinil's molecular structure is susceptible to oxidation and reduction during storage. API manufacturers must control moisture exposure and temperature during both synthesis and packaging to prevent degradation to the sulfone (inactive) or sulfide (different pharmacology) forms [11]. This chemical sensitivity has contributed to API quality variation among generic suppliers, a factor in several FDA warning letters discussed below.

FDA Shortage Timeline: 2015 to Present

Since generic entry, the FDA Drug Shortage Database has listed modafinil in multiple shortage events. The pattern reflects vulnerabilities common to off-patent, low-margin controlled substances where manufacturer consolidation reduces supply chain redundancy.

2015 to 2016 shortage. The first significant shortage occurred when Par Pharmaceutical (then a subsidiary of Endo International) temporarily halted production of its 200 mg tablets due to manufacturing delays. The FDA listed modafinil 200 mg as "currently in shortage" from late 2015 through mid-2016. Mylan and Teva partially compensated, but pharmacies reported intermittent difficulty sourcing 200 mg tablets for approximately eight months [4].

2019 shortage. A second shortage event was triggered by API supply disruptions. Multiple generic manufacturers sourced modafinil API from the same cluster of facilities in Hyderabad, India. When one major API supplier received an FDA Form 483 citing data integrity violations, the resulting supply gap cascaded to at least two finished-dosage manufacturers. This event coincided with a broader pattern: between 2018 and 2020, the FDA issued 29 warning letters to Indian pharmaceutical facilities for data integrity failures, as reported in the FDA's annual report to Congress on drug supply chain [12].

2022 to 2023 shortage. The most recent extended shortage began in late 2022 and persisted through portions of 2023. The American Society of Health-System Pharmacists (ASHP) Drug Shortage Resource Center documented this event, noting that multiple manufacturers (Aurobindo, Teva, and Mylan/Viatris) reported supply constraints simultaneously [13]. Contributing factors included increased demand (U.S. prescriptions grew from approximately 1.9 million in 2019 to 2.4 million in 2023), DEA manufacturing quota restrictions on Schedule IV substances, and ongoing API sourcing consolidation.

Dr. Erin Fox, Associate Chief Pharmacy Officer at University of Utah Health and a widely cited drug shortage expert, noted in 2023: "Modafinil shortages follow the same pattern we see with other generic controlled substances. When you have a small number of manufacturers all relying on the same API sources, any disruption at the ingredient level ripples through the entire finished-product supply" [14].

API Sourcing and Global Supply Chain Geography

The modafinil API supply chain is concentrated in India, with secondary capacity in China. This geographic concentration is a structural vulnerability that the FDA has acknowledged across multiple drug classes.

India accounts for an estimated 70% to 80% of global modafinil API production. The primary manufacturing cluster is in Hyderabad (Telangana state), where companies including MSN Laboratories, Aurobindo Pharma's API division, and several contract manufacturers operate. China-based API suppliers, primarily in Zhejiang and Jiangsu provinces, account for most of the remaining capacity [15].

The FDA's 2019 report "Drug Shortages: Root Causes and Potential Solutions" identified three structural drivers of shortages in the generic market: lack of incentives to manufacture less profitable drugs, supply chain fragility due to consolidation, and insufficient quality management at manufacturing facilities [16]. All three apply directly to modafinil.

DEA quota allocation adds another layer. As a Schedule IV controlled substance, modafinil is subject to annual aggregate production quotas set by the DEA under 21 CFR Part 1303. Manufacturers must apply for individual manufacturing quotas, and the DEA sets an aggregate ceiling based on projected medical need plus reserve. When demand increases faster than the DEA adjusts quotas (which are set annually with limited mid-year flexibility), manufacturers hit production ceilings even when they have the physical capacity and API inventory to produce more [17].

A 2023 analysis published in the Journal of the American Pharmacists Association estimated that DEA quota constraints contributed to shortages in at least 30% of Schedule II through IV generic drugs between 2018 and 2022 [18].

Quality and Regulatory Actions Affecting Supply

Multiple FDA regulatory actions have directly impacted modafinil supply availability.

In 2016, the FDA issued a warning letter to a Hyderabad-based API manufacturer supplying modafinil intermediates, citing failures in laboratory data integrity and out-of-specification (OOS) investigation procedures. The warning letter specifically noted that the facility failed to properly investigate OOS results for modafinil API potency assays, raising concerns about batch-to-batch consistency [12].

In 2018, the FDA's Office of Pharmaceutical Quality flagged bioequivalence study concerns with one ANDA holder's modafinil 200 mg product. The agency requested additional dissolution testing data before resuming distribution, creating a temporary supply gap for that manufacturer's product [4].

Compounding these specific events, the COVID-19 pandemic disrupted FDA foreign facility inspections between March 2020 and mid-2022. The FDA conducted zero routine inspections of Indian pharmaceutical facilities during calendar year 2020. This inspection backlog created a risk environment where quality problems at API facilities might go undetected longer than in pre-pandemic years [19].

The FDA Modernization Act 2.0 and subsequent guidance documents have attempted to address supply chain transparency. Section 506C of the FD&C Act requires manufacturers to notify the FDA at least six months before a meaningful supply disruption (or as soon as practicable). Compliance with this notification requirement remains inconsistent. An FDA analysis found that only 38% of shortage events between 2019 and 2022 were preceded by timely manufacturer notifications [16].

Current Manufacturer Roster and Supply Status

As of early 2026, the following manufacturers hold approved ANDAs for modafinil tablets in the U.S. market, according to the FDA Orange Book and Drugs@FDA database [20]:

Teva Pharmaceuticals (both brand Provigil NDA and generic ANDA), Mylan/Viatris, Par Pharmaceutical (Endo/Par), Aurobindo Pharma USA, Apotex, Hikma Pharmaceuticals, and Amneal Pharmaceuticals all hold approved applications. Not all ANDA holders actively market their products at any given time. Market participation depends on pricing, API availability, and DEA quota allocations.

The ASHP Drug Shortage Resource Center listed modafinil supply as "resolved" as of its most recent update, though the resource notes that supply stability for this product has historically been cyclical [13]. Prescribers should be aware that shortages tend to recur at 18- to 24-month intervals based on the historical pattern since 2015.

For patients affected by shortages, the FDA recommends contacting the prescriber to discuss therapeutic alternatives. Armodafinil (Nuvigil), the R-enantiomer of modafinil, is the closest pharmacologic substitute and has its own generic supply chain. Other wakefulness-promoting agents include solriamfetol (Sunosi) and pitolisant (Wakix), though these carry different indication profiles, insurance coverage, and cost structures [21].

What Prescribers and Patients Can Do During Shortages

The ASHP recommends that prescribers take a proactive approach: contact multiple pharmacies, consider 90-day fills when supply is available, and discuss alternative agents early rather than waiting for complete stockout. Splitting 200 mg tablets to create 100 mg doses is pharmacologically acceptable (the tablets are scored), though patients should confirm with their pharmacist.

Pharmacists should report shortage experiences to the FDA Drug Shortage Staff (drugshortages@fda.hhs.gov) and to the ASHP Drug Shortage Resource Center, as these reports inform quota adjustment requests and manufacturer communications [13]. Documentation of unmet demand is one of the few mechanisms that can trigger mid-year DEA quota adjustments under 21 CFR 1303.13.

Patients prescribed modafinil for narcolepsy (the original FDA-approved indication) generally have the strongest insurance coverage and prior authorization pathways. Those using modafinil off-label for fatigue, ADHD, or cognitive complaints may face additional formulary barriers during shortage periods because insurers tighten off-label dispensing when supply is constrained [22].